DRAK2 anticorps (Internal Region)

N° du produit ABIN499168

Détail du produit anti-DRAK2 anticorps

Antigène: DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))

Épitope: Internal Region

Reactivité: Humain, Chien

Hôte: Chèvre

Clonalité: Polyclonal

Conjugué: Cet anticorp DRAK2 est non-conjugé

Application: Western Blotting (WB)

Séquence: C-HSVRSSEDKT SK

Specificité: This antibody detects STK17B / DRAK2 (Internal).

Réactivité croisée (Details): Species reactivity (expected):DogSpecies reactivity (tested):Human

Purification: Ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide

Immunogène: Peptide from the internal region of the protein sequence according to NP_004217.1

Information d'application

Indications d'application: Peptide ELISA: antibody detection limit dilution 1: 32000. Western blot: 1-3 μg/mL. Approx 45 kDa band observed in lysates of cell line MOLT4(calculated MW of 42.5 kDa according to NP_004217.1).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at 2 - 8 °C up to one week or (in aliquots) at -20 °C for longer.

Détails sur DRAK2

Antigène: DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))

Autre désignation: STK17B / DRAK2 (STK17B Produits)

Synonymes: anticorps zgc:65989, anticorps STK17B, anticorps DRAK2, anticorps Drak2, anticorps 3110009A03Rik, anticorps AI120141, anticorps serine/threonine kinase 17b (apoptosis-inducing), anticorps serine/threonine kinase 17b, anticorps stk17b, anticorps STK17B, anticorps Stk17b

Sujet: Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase related apoptosis inducing protein kinases). DRAKs contain an N terminal kinase domain and a C terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues. Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP,are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases) (1). DRAKs contain anN-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.Synonyms: DAP kinase-related apoptosis-inducing protein kinase 2, Serine/threonine-protein kinase 17B

ID gène: 9262

NCBI Accession: NP_004217

UniProt: O94768